Phase 1 HER2 Clinical Trials
94 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 94 trials
Recruiting
Phase 1
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
HER2-positive Breast Cancer
University of Alabama at Birmingham25 enrolled1 locationNCT04332588
Recruiting
Phase 1
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Deborah Doroshow23 enrolled1 locationNCT04997993
Recruiting
Phase 1Phase 2
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 1
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 1Phase 2
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
HER2-Positive Solid Tumor
Yuhan Corporation147 enrolled19 locationsNCT05523947
Recruiting
Phase 1Phase 2
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Kristina A. Fanucci65 enrolled1 locationNCT07198724
Recruiting
Phase 1
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 1
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled4 locationsNCT07524322
Recruiting
Phase 1
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals194 enrolled2 locationsNCT07604571
Recruiting
Phase 1
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Endometrial CancerHER2-low Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Cogent Biosciences, Inc.90 enrolled2 locationsNCT07383506
Recruiting
Phase 1
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Metastatic Breast CancerHER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
BeOne Medicines120 enrolled15 locationsNCT06756932
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech36 enrolled1 locationNCT07622940
Recruiting
Phase 1
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1Phase 2
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech42 enrolled1 locationNCT07617805
Recruiting
Phase 1Phase 2
Elacestrant in Advanced Triple Positive Breast Cancer
ER Positive, HER2 Positive Breast Cancer
NYU Langone Health50 enrolled1 locationNCT07612215
Recruiting
Phase 1Phase 2
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Advanced ER+/HER2- Breast Cancer
Qilu Pharmaceutical Co., Ltd.300 enrolled1 locationNCT07235176